Department of Physiology & Pharmacology, University of Western Ontario, London, ON, Canada, N6A 5C1.
Mol Hum Reprod. 2010 Feb;16(2):57-62. doi: 10.1093/molehr/gap101. Epub 2009 Dec 1.
Rapid advancements have occurred in induced pluripotent stem cell research within the 3 years since Yamanaka and colleagues first reprogrammed adult mouse fibroblasts to an embryonic stem cell-like state by the forced expression of a small cohort of transcription factors. Progress has been made in overcoming various technical obstacles, including oncogenic threat, that hinder the application of iPS cell technology as a therapeutic strategy in humans. Remaining hurdles include the low efficiency of iPS cell induction and the demonstration of complete developmental potential. This latter impediment now appears to have been overcome simultaneously by two groups (Kristen Baldwin and colleagues and Qi Zhou and colleagues), who have generated viable adult mice from tetraploid complementation assays using iPS donor cells. The generation of sufficiently reprogrammed iPS cells and mice will allow for adequate genomic and functional testing to evaluate their utility in research applications and patient-specific cell replacement therapies, which may include infertility.
在山中伸弥（Shinya Yamanaka）及其同事首次通过强制表达一小群转录因子将成年小鼠成纤维细胞重编程为胚胎干细胞样状态以来的 3 年内，诱导多能干细胞研究取得了快速进展。在克服各种技术障碍方面取得了进展，包括抑制 iPS 细胞技术作为人类治疗策略的致癌威胁。仍然存在的障碍包括 iPS 细胞诱导效率低和完全发育潜力的证明。这一最后障碍现在似乎已被两个小组（Kristen Baldwin 及其同事和 Qi Zhou 及其同事）同时克服，他们使用 iPS 供体细胞进行四倍体互补测定生成了有活力的成年小鼠。足够数量的重编程 iPS 细胞和小鼠的生成将允许进行充分的基因组和功能测试，以评估它们在研究应用和患者特异性细胞替代疗法中的效用，这可能包括不孕症。
